Abstract
Combined dopamine D2 receptor antagonism and serotonin (5-HT)1A receptor agonism may improve efficacy and alleviate some side effects associated with classical antipsychotics. The present study describes the in vitro and in vivo characterization of 1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4-[5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride (SLV313), a D2/3 antagonist and 5-HT1A agonist. SLV313 possessed high affinity at human recombinant D2, D3, D4, 5-HT2B, and 5-HT1A receptors, moderate affinity at 5-HT7 and weak affinity at 5-HT2A receptors, with little-no affinity at 5-HT4, 5-HT6, α1, and α2 (rat), H1 (guinea pig), M1, M4, 5-HT3 receptors, and the 5-HT transporter. SLV313 had full agonist activity at cloned h5-HT1A receptors (pEC50=9.0) and full antagonist activity at hD2 (pA2=9.3) and hD3 (pA2=8.9) receptors. In vivo, SLV313 antagonized apomorphine-induced climbing and induced 5-HT1A syndrome behaviors and hypothermia, the latter behaviors being antagonized by the 5-HT1A antagonist WAY100635. In a drug discrimination procedure SLV313 induced full generalization to the training drug flesinoxan and was also antagonized by WAY100635. In the nucleus accumbens SLV313 reduced extracellular 5-HT and increased dopamine levels in the same dose range. Acetylcholine and dopamine were elevated in the hippocampus and mPFCx, the latter antagonized by WAY100635, suggesting possible 5-HT1A-dependent efficacy for the treatment of cognitive and attentional processes. SLV313 did not possess cataleptogenic potential (up to 60 mg/kg p.o.). The number of spontaneously active dopamine cells in the ventral tegmental area was reduced by SLV313 and clozapine, while no such changes were seen in the substantia nigra zona compacta following chronic administration. These results suggest that SLV313 is a full 5-HT1A receptor agonist and full D2/3 receptor antagonist possessing characteristics of an atypical antipsychotic, representing a potential novel treatment for schizophrenia.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Assie MB, Ravailhe V, Faucillon V, Newman-Tancredi A (2005). Contrasting contribution of 5-HT1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 315: 265–272.
Bantick RA, Deakin JF, Grasby PM (2001). The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 15: 37–46.
Berendsen HH, Jenck F, Broekkamp CL (1989). Selective activation of 5HT1A receptors induces lower lip retraction in the rat. Pharmacol Biochem Behav 33: 821–827.
Bill DJ, Knight M, Forster EA, Fletcher A (1991). Direct evidence for an important species difference in the mechanism of 8-OH-DPAT-induced hypothermia. Br J Pharmacol 103: 1857–1864.
Bonhaus DW, Bach C, DeSouza A, Salazar FH, Matsuoka BD, Zuppan P et al (1995). The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. Br J Pharmacol 115: 622–628.
Bristow LJ, Collinson N, Cook GP, Curtis N, Freedman SB, Kulagowski JJ et al (1997a). L-745, 870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests. J Pharmacol Exp Ther 283: 1256–1263.
Bristow LJ, Kramer MS, Kulagowski J, Patel S, Ragan CI, Seabrook GR (1997b). Scizophrenia and L-745, 870, a novel dopamine D4 receptor antagonist. TIPS 18: 186–188.
Bunzow JR, Van Tol HH, Grandy DK, Albert P, Salon J, Christie M et al (1988). Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 336: 783–787.
Burnet PW, Eastwood SL, Harrison PJ (1996). 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 15: 442–555.
Casey DE (1996). Extrapyramidal syndromes and new antipsychotic drugs: findings in patients and non-human primate models. Br J Psychiatr 29: 32–39.
Chiodo LA (1988). Dopamine-containing neurons in the mammalian central nervous system: electrophysiology and pharmacology. Neurosci Biobehav 12: 49–91.
Chiodo LA, Bunney BS (1983). Typical and atypical neuroleptics: Differential effects of chronic administration on the activity of A9 and A10 dopamine neurons. J Neurosci 7: 1607–1619.
Christoffersen CL, Meltzer LT (1998). Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino)tetralin and its enantiomers. Neuropsychopharmacology 18: 399–402.
Chung YC, Li Z, Dai J, Meltzer HY, Ichikawa J (2004). Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT(1A) receptor agonism. Brain Res 1023: 54–63.
Claustre Y, Peretti DD, Brun P, Gueudet C, Allouard N, Alonso R et al (2003). SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile. Neuropsychopharmacology 28: 2064–2076.
Depoortere R, Boulay D, Perrault G, Bergis O, Decobert M, Francon D et al (2003). SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity. Neuropsychopharmacology 28: 1889–1902.
Dini S, Caselli GF, Ferrari MP, Giani R, Clavenna G (1991). Heterogeneity of [3H]-mepyramine binding sites in guinea pig cerebellum and lung. Agents Actions 33: 181–184.
Dorje F, Wess J, Lambrecht G, Tackle R, Mutschler E, Brann MR (1991). Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol Exp Ther 256: 727–733.
Eichenbaum H, Dudchenko P, Wood E, Shapiro M, Tanila H (1999). The hippocampus, memory, and place cells: is it spatial memory or a memory space? Neuron 23: 209–226.
Fargin A, Raymond JR, Regan JW, Cotecchia S, Lefkowitz RJ, Caron MG (1989). Effector coupling mechanisms of the cloned 5-HT1A receptor. J Biol Chem 64: 14848–14852.
Fernandez G, Klaver P, Fell J, Grunwald T, Elger CE (2002). Human declarative memory formation: segregating rhinal and hippocampal contributions. Hippocampus 12: 514–519.
Freeman AS, Bunney BS (1987). Chronic neuroleptic effects on DA neuron activity: a model for predicting therapeutic efficacy and side effects? Psychopharmacol Ser 3: 225–235.
Goff DC, Midha KK, Brotman AW, McCormick S, Waites M, Amico ET (1991). An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 11: 193–197.
Goldman-Rakic PS (1998). The cortical dopamine system: role in memory and cognition. Adv Pharmacol 42: 707–711.
Grandy DK, Marchionni MA, Makam H, Stofko RE, Alfano M, Frothingham L et al (1989). Cloning of the cDNA and gene for a human D2 DA receptor. Proc Natl Acad Sci USA 86: 9762–9766.
Greengrass P, Bremner R (1979). Binding characteristics of 3H-prazosin to rat brain alpha-adrenergic receptors. Eur J Pharmacol 55: 323–326.
Gurevich EV, Joyce JN (1997). Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol Psychiatr 42: 529–545.
Hartfield AW, Moore NA, Clifton PG (2003). Serotonergic and histaminergic mechanisms involved in intralipid drinking? Pharmacol Biochem Behav 76: 251–258.
Harvey PD, Keefe RS (2001). Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatr 158: 176–184.
Herremans AHJ, van der Heyden JAM, van Drimmelen M, Olivier B (1999). The 5-HT1A agonist flesinoxan shares discriminative stimulus properties with some 5-HT2 receptor antagonists. Pharmacol Biochem Behav 64: 389–395.
Hertel P, Nomikos GG, Iurlo M, Svensson TH (1996). Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology (Berlin) 124: 74–86.
Hope AG, Peters JA, Brown AM, Lambert JJ, Blackburn TP (1996). Characterization of a human 5-hydroxytryptamine3 receptor type A (h5-HT3R-AS) subunit stably expressed in HEK 293 cells. Br J Pharmacol 118: 1237–1245.
Ichikawa J, Dai J, Meltzer HY (2002a). 5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex. Brain Res 939: 34–42.
Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY (2002b). Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26: 325–339.
Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY (2001). 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76: 1521–1531.
Ichikawa J, Meltzer HY (1999). R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J Pharmacol Exp Ther 291: 1227–1232.
Jones-Humble SA, Durcan MJ, Lyerly D, Norton MS, Tang FLM, Russell AV et al (1996). Preclinical neurochemical and electrophysiological profile of 1192U90, a potential antipsychotic. Neuropsychopharmacology 15: 217–229.
Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA (2002). The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441: 137–140.
Joyce JN, Millan MJ (2005). Dopamine D3 receptor antagonists as therapeutic agents. Drug Discovery Today 10: 917–925.
Kleven MS, Prinssen EPM, Koek W, Grevoz-Barret C, Newman-Tancredi A (2003). In vivo pharmacology of novel antipsychotics having mixed D2 antagonist/5HT1A agonist properties: evidence for lowered EPS liability. Soc Neurosci Abstr 33: 956.2.
Kuroki T, Meltzer HY, Ichikawa J (1999). Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288: 774–781.
Lejeune F, Audinot V, Gobert A, Rivet JM, Spedding M, Millan MJ (1994). Clozapine inhibits serotoninergic transmission by an action at alpha 1-adrenoceptors not at 5-HT1A receptors. Eur J Pharmacol 260: 79–83.
Li Z, Ichikawa J, Dai J, Meltzer HY (2004). Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 493: 75–83.
Mackenzie RG, Vanleeuven D, Pugsley TA, Shih Y-H, Demattos S, Tang L et al (1994). Characterization of the human dopamine D3 receptor expressed in transfected cell lines. Eur J Pharmacol 266: 79–85.
McCreary AC, Glennon JC, Tuinstra T, Herremans AHJ, Van der Heyden J, Long SK et al (2002). SLV313: a novel antipsychotic with additional antidepressant and anxiolytic-like acitons. Eur Neuropsychopharmacol 12: S274.
Meltzer HY (1999). The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 2: 106–115.
Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003). Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27: 1159–1172.
Meltzer HY, McGurk SR (1999). The effect of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophrenia Bull 25: 233–255.
Mialet J, Berque-Bestel I, Sicsic S, Langlois M, Fischmeister R, Lezoualc'h F (2000). Pharmacological characterization of the human 5-HT(4(d)) receptor splice variant stably expressed in Chinese hamster ovary cells. Br J Pharmacol 131: 827–835.
Millan MJ (2000). Improving the treatment of schizophrenia: focus on serotonin (5-HT)1A receptors. J Pharmacol Exp Ther 295: 853–861.
Moghaddam B, Bunney BS (1990). Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54: 1755–1760.
Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR (1993). Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 43: 320–327.
Mos J, van Hest A, van Drimmelen M, Herremans AHJ, Olivier B (1997). The putative 5-HT1A receptor antagonist DU125530 blocks the discriminative stimulus properties of the 5-HT1A agonist flesinoxan in pigeons. Eur J Pharmacol 325: 145–153.
Mulheron JG, Casanas SJ, Arthur JM, Garnovskaya MN, Gettys TW, Raymond JR (1994). Human 5-HT1A receptor expressed in insect cells activates endogenous G(o)-like G protein(s). J Biol Chem 269: 12954–12962.
Nakamura K, Suzuki K, McCreary AC, Ashby Jr CR (2006). The acute and chronic administration of (±)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) significantly alters the activity of spontaneously active midbrain dopamine neurons in rats: an in vivo electrophysiological study. Synapse 59: 359–367.
Newman-Tancredi A, Assie M-B, Leduc N, Ormiere A-M, Danty N, Cosi C (2004). Novel antipsychotics activate recombinant human and native rat serotinin 5-HT1A receptors: affinity, efficacy and potential implications for the treatment of scizophrenia. Int J Neuropsychopharmacol 8: 1–16.
Newman-Tancredi A, Audinot V, Chaput C, Verriele L, Millan MJ (1997). [35S]Guanosine-5′-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents. J Pharmacol Exp Ther 282: 181–191.
Newman-Tancredi A, Chaput C, Verriele L, Millan MJ (1996). Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors. Neuropharmacology 35: 119–121.
Newman-Tancredi A, Cussac D, Audinot V, Pasteau V, Gavaudan S, Millan MJ (1999). G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: a guanosine-5′-O-(3-[35S]thio)-triphosphate binding and antibody study. Mol Pharmacol 55: 564–574.
Newman-Tancredi A, Verriele L, Touzard M, Millan MJ (2001). Efficacy of antipsychotic agents at human 5-HT(1A) receptors determined by [3H]WAY100, 635 binding affinity ratios: relationship to efficacy for G-protein activation. Eur J Pharmacol 428: 177–184.
Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH (1994). Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacol (Berlin) 115: 147–156.
Paxinos G, Watson C (1998). The Rat Brain In Stereotaxic Coordinates. Academic Press: New York.
Pehek EA, Meltzer HY, Yamamoto BK (1993). The atypical antipsychotic drug amperozide enhances rat cortical and striatal dopamine efflux. Eur J Pharmacol 240: 107–109.
Prinssen EP, Kleven MS, Koek W (1996). Effects of dopamine antagonists in a two-way active avoidance procedure in rats: interactions with 8-OH-DPAT, ritanserin, and prazosin. Psychopharmacology 128: 191–197.
Prinssen EP, Kleven MS, Koek W (1999). Interactions between neuroleptics and 5-HT(1A) ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacology 144: 20–29.
Prinssen EP, Koek W, Colpaert FC, Kleven MS (2000). Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy. Behav Pharmacol 11: 299–305.
Reynolds GP, Zhang ZJ, Zhang XB (2002). Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 359: 2086–2087.
Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH (2000). 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatr 48: 229–237.
Rollema H, Lu Y, Schmidt AW, Zorn SH (1997). Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol 338: R3–R5.
Salomon Y, Londos C, Rodbell M (1974). A highly selective adenylate cyclase assay. Analyt Biochem 58: 541–548.
Seeman P, Lee T, Chau-Wong M, Wong K (1976). Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261: 717–719.
Seidman LG, Kremen WS, Koren D, Faraone SV, Goldstein JM, Tsuang MT (2002). A comparative profile analysis of neuropsychological functioning in patients with schizophrenia and bipolar psychoses. Schizophren Res 53: 31–44.
Shen Y, Monsma FJ, Metcalf MA, Jose PA, Hamblin MW, Sibley DR (1993). Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J Biol Chem 268: 18200–18204.
Shirazi-Southall S, Rodriguez DE, Nomikos GG (2002). Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26: 583–594.
Sprouse JS, Reynolds LS, Braselton JP, Rollema H, Zorn SH (1999). Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacology 21: 622–631.
Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C et al (2001a). Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatr 158: 1722–1725.
Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Kurachi M, Uehara T et al (2001b). The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiatr 15: 861–868.
Tatsumi M, Groshan K, Blakeley RD, Richelson E (1997). Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340: 249–258.
Tricklebank MD, Forler C, Fozard JR (1984). The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioral response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur J Pharmacol 106: 271–282.
Uhlen S, Wikberg JE (1991). Rat spinal cord alpha 2-adrenoceptors are of the alpha2A-subtype: comparison with alpha2A- and alpha2B-adrenoceptors in rat spleen, cerebral cortex and kidney using 3H-RX821002 ligand binding. Pharmacol Toxicol 69: 341–350.
Van Tol HH, Wu CM, Guan HC, Ohara K, Bunzow JR, Civelli O et al (1992). Multiple DA D4 receptor variants in the human population. Nature 358: 149–152.
Wadenberg ML (1996). Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci Biobehav Rev 20: 325–339.
Wadenberg ML, Ahlenius S (1991). Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J Neural Transm 83: 43–53.
Wadenberg ML, Young KA, Richter JT, Hicks PB (1999). Effects of local application of 5-hydroxytryptamine into the dorsal or median raphe nuclei on haloperidol-induced catalepsy in the rat. Neuropharmacology 38: 151–156.
Weinberger DR, Lipska BK (1995). Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophren Res 16: 87–110.
Weiss S, Sebben M, Bockaert JJ (1985). Corticotropin-peptide regulation of intracellular cyclic AMP production in cortical neurons in primary culture. J Neurochem 45: 869–874.
White FJ, Wang RY (1983). Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221: 1054–1057.
Winstanley CA, Chudasama Y, Dalley JW, Theobald DE, Glennon JC, Robbins TW (2003). Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats. Psychopharmacology (Berlin) 167: 304–314.
Wolff MC, Wainscott DB, Nelson DL, Moore NA, Overshiner CD, Leander JD et al (2003). An in vivo assessment of aripiprazole, ziprasidone, risperidone and olanzapine in rat assays indicative of 5-HT1A and D2 receptor activity Schizophren. Research 60 (S 1): 119.
Yasuno F, Suhara T, Ichimiya T, Takano A, Ando T, Okubo Y (2004). Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biol Psychiatr 55: 439–444.
Yoshida K, Sugita T, Higuchi H, Hishikawa Y (1998). Effects of tandospirone on tardive dyskinesia and parkinsonian symptoms. Eur Psychol 13: 421–422.
Acknowledgements
We acknowledge the technical assistance of the in vitro and in vivo pharmacology research groups of Solvay Pharmaceuticals Research and the suggestions of Dr Karen Marquis of Wyeth Research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
McCreary, A., Glennon, J., Ashby, C. et al. SLV313 (1-(2,3-Dihydro-Benzo[1,4]Dioxin-5-yl)-4- [5-(4-Fluoro-Phenyl)-Pyridin-3-ylmethyl]-Piperazine Monohydrochloride): A Novel Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist Potential Antipsychotic Drug. Neuropsychopharmacol 32, 78–94 (2007). https://doi.org/10.1038/sj.npp.1301098
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1301098
Keywords
This article is cited by
-
Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models
Psychopharmacology (2012)
-
The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in rats
Psychopharmacology (2012)
-
Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties
Psychopharmacology (2011)
-
Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics
Advances in Therapy (2008)
-
Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties
Naunyn-Schmiedeberg's Archives of Pharmacology (2007)
